2025年2月17日,来自美国贝勒医学院细胞与基因治疗中心的Helen E. Heslop教授研究团队在Nature Medicine上发表题为Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma的文章,研究描述了CAR-T治疗活动性恶性肿瘤后报告的最长生存期,表明GD2 CAR-ATC/VST疗法可安全地在难治性/复发...
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany Article Open access 22 March 2021 References Stancovski, I. et al. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151, 6577–6582 (1993). CA...
infusion has been shown to be safe and tolerable in recent clinical trials for treatment of multiple sclerosis and Parkinson’s disease62. We therefore envision that metabolic modulation of T cells, including through inosine and PEG–ADA supplementation, poses a new complementary strategy to optimize...
In this review, we summarize the application of CRISPR–Cas9 on T cell activation, differentiation, and function. First, we describe the CRISPR–Cas9 application on different T cells. We then discuss its application in the adoptive T cells therapies in preclinical and clinical research. Finally, ...
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122(17):2965-2973. Blood, Volume 123, Issue 21, 22 May 2014, Pages 3364 View PDF...
The median time to receiving T-cell–redirecting therapy after diagnosis was 63.7 months (range, 7.6-286.5 months). No significant differences in this time were observed between the CAR-T and BiAbs groups (63.3 vs 65.3 months; P = .557). Clinical characteristics and prior lines of therapies...
This chapter will focus on the exciting development in cellular therapy in the context of HCT and cell therapy including discussion of the diverse repertoire of T-cell products, specifically donor lymphocyte infusion (DLI), regulatory T cells, cytotoxic T lymphocytes for viral infections, and T-...
Between February 22, 2017, and September 26, 2019, a total of 61 subjects (EMM 25; non-EMM 36) received anti-BCMA CAR-T cell infusion. The data-cutoff date was April 1, 2021. There were no statistical differences between EMM and non-EMM groups in adverse events (AEs), including ...
115 However, the patient cohorts in these studies were small and highly diverse, in terms of cancer type, additional therapy and composition of the T cell infusion. These variables make it difficult to assign the exact clinical contribution of γδ T cells. ACT of γδ T cells and other ...
dehydrogenase (LDH) or monocyte chemoattractant protein-1 (MCP-1)2,3, and a host of T-cell-intrinsic determinants3 aside from CAR construct design1, including the CD4-to-CD8 ratio4,5, and distinct T-cell subpopulations in the apheresis material6 and in the CAR-T cell infusion product7,...